<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-09384R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0005489</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Developmental Biology/Microbial Growth and Development</subject><subject>Molecular Biology/Translational Regulation</subject><subject>Virology/Animal Models of Infection</subject><subject>Virology/Immune Evasion</subject><subject>Virology/Persistence and Latency</subject><subject>Virology/Viral Replication and Gene Regulation</subject><subject>Gastroenterology and Hepatology/Hepatology</subject><subject>Infectious Diseases/Viral Infections</subject></subj-group></article-categories><title-group><article-title>Developmental Regulation of Hepatitis B Virus Biosynthesis by Hepatocyte Nuclear Factor 4&#x003b1;</article-title><alt-title alt-title-type="running-head"><italic>In Vivo</italic> Regulation of HBV</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Lie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Oropeza</surname><given-names>Claudia E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sainz</surname><given-names>Bruno</given-names><suffix>Jr.</suffix></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Uprichard</surname><given-names>Susan L.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gonzalez</surname><given-names>Frank J.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>McLachlan</surname><given-names>Alan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Microbiology and Immunology College of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Medicine, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Ganem</surname><given-names>Donald E.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of California San Francisco, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>mclach@uic.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: AM. Performed the experiments: LL CEO BS AM. Analyzed the data: LL CEO BS AM. Contributed reagents/materials/analysis tools: FJG. Wrote the paper: SLU AM.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>8</day><month>5</month><year>2009</year></pub-date><volume>4</volume><issue>5</issue><elocation-id>e5489</elocation-id><history><date date-type="received"><day>24</day><month>3</month><year>2009</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2009</year></date></history><copyright-statement>Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><p>The host cellular factors that promote persistent viral infections <italic>in vivo</italic> are, in general, poorly understood. Utilizing the hepatitis B virus (HBV) transgenic mouse model of chronic infection, we demonstrate that the nuclear receptor, hepatocyte nuclear factor 4&#x003b1; (HNF4&#x003b1;, NR2A1), is essential for viral biosynthesis in the liver. The dependency of HBV transcription on HNF4&#x003b1; links viral biosynthesis and persistence to a developmentally regulated transcription factor essential for host viability.</p></abstract><counts><page-count count="7"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Persistent viral infections require the coexistence of pathogen and host for extended periods of time without the host resolving the infection or the virus killing the host. Human immunodeficiency virus, herpes simplex viruses, papillomaviruses and hepatitis B and C virus have evolved a variety of strategies to persistently infect man <xref ref-type="bibr" rid="pone.0005489-Geeraert1">&#x0005b;1&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005489-Gale1">&#x0005b;4&#x0005d;</xref>. HBV chronically infects approximately 400 million people worldwide resulting in about a million deaths per year from liver cirrhosis and hepatocellular carcinoma <xref ref-type="bibr" rid="pone.0005489-Lok1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005489-Lavanchy1">&#x0005b;6&#x0005d;</xref>. Most HBV infections worldwide occur in neonates at or around the time of birth and usually result in persistent infections <xref ref-type="bibr" rid="pone.0005489-Lavanchy1">&#x0005b;6&#x0005d;</xref>. Although the immunological immaturity of the neonate is presumed to contribute to these chronic HBV infections, a precise understanding of the molecular events governing HBV persistence during development is lacking.</p><p>HBV replicates its genomic DNA by reverse transcription of a pregenomic 3.5kb RNA which is transcribed from covalently closed circular 3.2kb viral genomic DNA in the nucleus of infected hepatocytes <xref ref-type="bibr" rid="pone.0005489-Will1">&#x0005b;7&#x0005d;</xref>. Thus transcriptional regulation plays a central role in controlling viral replication levels <xref ref-type="bibr" rid="pone.0005489-Tang1">&#x0005b;8&#x0005d;</xref> and represents a potential antiviral target which has not, to date, been exploited clinically. In cell culture, the binding of hepatocyte nuclear factor 4&#x003b1; (HNF4&#x003b1;) or retinoid X receptor &#x003b1; (RXR&#x003b1;) plus peroxisome proliferator-activated receptor &#x003b1; (PPAR&#x003b1;) to the nucleocapsid promoter regulatory elements governs the level of synthesis of this critical HBV pregenomic 3.5kb RNA template <xref ref-type="bibr" rid="pone.0005489-Tang2">&#x0005b;9&#x0005d;</xref>.</p><p>In this study, we demonstrate that the level of HBV transcription and replication throughout early postnatal development correlates with the level of liver HNF4&#x003b1; expression in the HBV transgenic mouse model of chronic HBV infection. The conditional depletion of HNF4&#x003b1; in the liver results in the loss of HBV transcription and replication indicating that this nuclear receptor is a major determinant of viral biosynthesis <italic>in vivo</italic>. These observations indicate that viral transcription, biosynthesis and antigen expression will increase progressively after infection at birth, possibly contributing to persistent infection. Additionally, the essential nature of the HNF4&#x003b1; transcription factor for host viability <xref ref-type="bibr" rid="pone.0005489-Hayhurst1">&#x0005b;10&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005489-Chen1">&#x0005b;12&#x0005d;</xref> may limit the hosts' ability to resolve infection and increase the probability of viral persistence.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Characterization of the conditional liver-specific HNF4&#x003b1; deficient HBV transgenic mouse during early postnatal development</title><p>Using the HBV transgenic mouse (lineage 1.3.32) model of chronic infection <xref ref-type="bibr" rid="pone.0005489-Guidotti1">&#x0005b;13&#x0005d;</xref>, we previously demonstrated that PPAR&#x003b1; did not affect the level of viral biosynthesis under normal physiological conditions but did mediate enhanced viral transcription and replication in response to peroxisome proliferators <xref ref-type="bibr" rid="pone.0005489-Guidotti2">&#x0005b;14&#x0005d;</xref>. To determine the role of the transcription factor HNF4&#x003b1; in HBV biosynthesis, we bred HBV transgenic mice with mice carrying a floxed HNF4&#x003b1; (<italic>HNF4&#x003b1;</italic><sup>fl/fl</sup>) allele <xref ref-type="bibr" rid="pone.0005489-Hayhurst1">&#x0005b;10&#x0005d;</xref> and albumin Cre recombinase (lineage B6.Cg-Tg(Alb-cre)21Mgn/J, Jackson Laboratory) transgene (AlbCre) <xref ref-type="bibr" rid="pone.0005489-Postic1">&#x0005b;15&#x0005d;</xref> to generate HBVAlbCreHNF4&#x003b1;<sup>fl/fl</sup> transgenic mice. The presence of the AlbCre transgene in the HNF4&#x003b1;<sup>fl/fl</sup> mice results in the postnatal liver-specific loss of exons 4 and 5 of the <italic>HNF4&#x003b1;</italic> gene <xref ref-type="bibr" rid="pone.0005489-Hayhurst1">&#x0005b;10&#x0005d;</xref>.</p><p>From the initial crosses generating HBVAlbCreHNF4&#x003b1;<sup>fl/fl</sup> transgenic mice, it was apparent that some of the pups were not growing at the same rate as their littermates (<xref ref-type="fig" rid="pone-0005489-g001">Figure 1A and B</xref>). Indeed, these pups were approximately 50&#x00025; the weight of their littermates between age 1 and 2 weeks (<xref ref-type="fig" rid="pone-0005489-g001">Figure 1B</xref>) and failed to survive past 16 days. Genotyping of these mice demonstrated that all the pups with reduced growth were Cre positive (sCre(&#x0002b;); small, Cre positive). However, many of the Cre positive mice (Cre(&#x0002b;)) within the same litter displayed growth rates closer to normal mice (Cre(&#x02212;); HNF4&#x003b1;<sup>fl/fl</sup> transgenic mice lacking the AlbCre transgene) (<xref ref-type="fig" rid="pone-0005489-g001">Figure 1B</xref>). While the liver to body weight ratio was similar (3.5&#x0002b;/&#x02212;0.6&#x00025;) for the different groups of mice throughout the first two weeks of postnatal development, the sCre(&#x0002b;) mice displayed additional features not observed in the other two groups. sCre(&#x0002b;) mice sera displayed a light yellow-green coloration that became more apparent with age. Additionally, the livers of approximately two thirds of the 1- to 2-week-old sCre(&#x0002b;) mice displayed an olive-yellow coloration rather than the dark red-brown color typically observed in normal mice. Both of these observations are consistent with the sCre(&#x0002b;) mice having an altered phenotype due to loss of HNF4&#x003b1; in the liver. The observed changes in color of the sera and livers may be due to modest increases in circulating bile acids seen in these mice (Cre(&#x02212;), Cre(&#x0002b;) and sCre(&#x0002b;) were 17&#x0002b;/&#x02212;9 &#x000b5;mol/l, 21&#x0002b;/&#x02212;6 &#x000b5;mol/l and 54&#x0002b;/&#x02212;15 &#x000b5;mol/l, respectively) <xref ref-type="bibr" rid="pone.0005489-Hayhurst1">&#x0005b;10&#x0005d;</xref> or an accumulation of the green pigment, biliverdin, a breakdown product of heme <xref ref-type="bibr" rid="pone.0005489-Fenech1">&#x0005b;16&#x0005d;</xref>. Similar to adult mice lacking HNF4&#x003b1; in their livers, the sCre(&#x0002b;) pups also had reduced circulating glucose (<xref ref-type="fig" rid="pone-0005489-g001">Figure 1C</xref>) consistent with lower HNF4&#x003b1; regulated gluconeogenesis in the liver <xref ref-type="bibr" rid="pone.0005489-Hayhurst1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005489-Rhee1">&#x0005b;17&#x0005d;</xref>.</p><fig id="pone-0005489-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005489.g001</object-id><label>Figure 1</label><caption><title>Effects of liver-specific conditional deletion of HNF4&#x003b1; on postnatal growth, serum glucose and HNF4&#x003b1; transcript levels.</title><p>(A) HBVAlbCre(&#x0002b;)HNF4&#x003b1;<sup>fl/fl</sup> pup with the small phenotype, sCre(&#x0002b;), and a control HBVAlbCre(&#x02212;)HNF4&#x003b1;<sup>fl/fl</sup> littermate, Cre(&#x02212;), at 5.5 days of age. (B) Effect of postnatal age on body weight. (C) Effect of postnatal age on serum glucose levels. (D) Effect of postnatal age on wild-type HNF4&#x003b1; RNA levels in the liver measured by reverse transcription-quantitative polymerase chain reaction. Cre(&#x02212;), control HBVAlbCre(&#x02212;)HNF4&#x003b1;<sup>fl/fl</sup> mice; Cre(&#x0002b;), HBVAlbCre(&#x0002b;)HNF4&#x003b1;<sup>fl/fl</sup> mice with approximately wild-type phenotype; sCre(&#x0002b;), HBVAlbCre(&#x0002b;)HNF4&#x003b1;<sup>fl/fl</sup> mice with the small phenotype.</p></caption><graphic xlink:href="pone.0005489.g001"/></fig><p>Wild-type HNF4&#x003b1; transcript levels were measured in the liver using reverse transcription-quantitative polymerase chain reaction analysis specific for HNF4&#x003b1; exons 4 and 5 (<xref ref-type="fig" rid="pone-0005489-g001">Figure 1D</xref>) <xref ref-type="bibr" rid="pone.0005489-Hayhurst1">&#x0005b;10&#x0005d;</xref>. This analysis demonstrated that while HNF4&#x003b1; levels increased during early postnatal development (<xref ref-type="fig" rid="pone-0005489-g001">Figure 1D</xref>), the sCre(&#x0002b;) pups had considerably lower levels of functional HNF4&#x003b1; transcripts compared to the Cre(&#x0002b;) or Cre(&#x02212;) mice throughout this time period, consistent with their observed phenotype. Additionally, sCre(&#x0002b;) mice with altered sera and liver coloration were never observed after 16 days, suggesting that these pups either died due to the lack of HNF4&#x003b1; in their hepatocytes or partially recovered as synthesis of HNF4&#x003b1; returned to an adequate level during liver development presumably due to the outgrowth of hepatocytes where the HNF4&#x003b1; gene was not efficiently deleted by the Cre recombinase.</p></sec><sec id="s2b"><title>Characterization of viral transcription in the conditional liver-specific HNF4&#x003b1; deficient HBV transgenic mouse during early postnatal development</title><p>These distinct groups of HBV transgenic mice (Cre(&#x02212;), Cre(&#x0002b;) and sCre(&#x0002b;)) exhibiting different levels of functional HNF4&#x003b1; expression throughout early postnatal development permitted the role of HNF4&#x003b1; in viral transcription and replication in the liver to be determined (<xref ref-type="fig" rid="pone-0005489-g002">Figures 2</xref> and <xref ref-type="fig" rid="pone-0005489-g003">3</xref>). Wild-type HBV transgenic mice (Cre(&#x02212;)) displayed about a ten-fold increase in HBV 3.5kb RNA from birth to two weeks of age (<xref ref-type="fig" rid="pone-0005489-g002">Figure 2</xref>). During the same time period, HNF4&#x003b1; levels increased approximately five-fold (<xref ref-type="fig" rid="pone-0005489-g001">Figure 1D</xref>). The Cre(&#x0002b;) mice which display slightly reduced levels of HNF4&#x003b1; in their liver also showed reduced viral transcription (<xref ref-type="fig" rid="pone-0005489-g002">Figure 2</xref>) while the sCre(&#x0002b;) mice, exhibiting a major reduction in HNF4&#x003b1; levels throughout this period of development, displayed drastically reduced levels of HBV transcription (<xref ref-type="fig" rid="pone-0005489-g002">Figure 2</xref>). Together these data demonstrate a clear correlation between the abundance of HBV transcripts <italic>in vivo</italic> and the level of HNF4&#x003b1; during development indicating that HNF4&#x003b1; is essential for viral RNA synthesis.</p><fig id="pone-0005489-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005489.g002</object-id><label>Figure 2</label><caption><title>HBV RNA transcripts in the livers of HBV transgenic mice throughout early postnatal development.</title><p>(A) RNA (Northern) filter hybridization analysis of representative examples of HBV transcripts at various stages of postnatal liver development. The glyceraldehyde 3-phosphate dehydrogenase (GAPDH) transcript was used as an internal control for the quantification of the HBV 3.5 and 2.1kb RNAs. The probes used were HBV<italic>ayw</italic> genomic DNA plus GAPDH cDNA<xref ref-type="bibr" rid="pone.0005489-Anderson1">&#x0005b;26&#x0005d;</xref>. Cre(&#x02212;), control HBVAlbCre(&#x02212;)HNF4&#x003b1;<sup>fl/fl</sup> mice; Cre(&#x0002b;), HBVAlbCre(&#x0002b;)HNF4&#x003b1;<sup>fl/fl</sup> mice with approximately wild-type phenotype; sCre(&#x0002b;), HBVAlbCre(&#x0002b;)HNF4&#x003b1;<sup>fl/fl</sup> mice with the small phenotype. (B) Quantitative analysis of the HBV 3.5kb transcript in HBVAlbCreHNF4&#x003b1;<sup>fl/fl</sup> transgenic mice. Trend lines were calculated using linear regression analysis.</p></caption><graphic xlink:href="pone.0005489.g002"/></fig><fig id="pone-0005489-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005489.g003</object-id><label>Figure 3</label><caption><title>HBV DNA replication intermediates in the livers of HBV transgenic mice throughout early postnatal development.</title><p>(A) DNA (Southern) filter hybridization analysis of representative examples of HBV replication intermediates (RI) at various stages of postnatal liver development. The HBV transgene (Tg) was used as an internal control for the quantification of the HBV replication intermediates. The probe used was HBV<italic>ayw</italic> genomic DNA<xref ref-type="bibr" rid="pone.0005489-Anderson1">&#x0005b;26&#x0005d;</xref>. Cre(&#x02212;), control HBVAlbCre(&#x02212;)HNF4&#x003b1;<sup>fl/fl</sup> mice; Cre(&#x0002b;), HBVAlbCre(&#x0002b;)HNF4&#x003b1;<sup>fl/fl</sup> mice with approximately wild-type phenotype; sCre(&#x0002b;), HBVAlbCre(&#x0002b;)HNF4&#x003b1;<sup>fl/fl</sup> mice with the small phenotype; Tg , HBV transgene; RC, HBV relaxed circular replication intermediates; SS, HBV single stranded replication intermediates. (B) Quantitative analysis of the HBV replication intermediates in HBVAlbCreHNF4&#x003b1;<sup>fl/fl</sup> transgenic mice. Trend lines were calculated using linear regression analysis.</p></caption><graphic xlink:href="pone.0005489.g003"/></fig></sec><sec id="s2c"><title>Characterization of viral replication in the conditional liver-specific HNF4&#x003b1; deficient HBV transgenic mouse during early postnatal development</title><p>The lower levels of viral 3.5kb pregenomic RNA associated with diminished HNF4&#x003b1; abundance in the liver resulted in similarly reduced HBV replication (<xref ref-type="fig" rid="pone-0005489-g003">Figure 3</xref>). In agreement with the observed reduction of HNF4&#x003b1; (<xref ref-type="fig" rid="pone-0005489-g001">Figure 1D</xref>), the Cre(&#x0002b;) mice displayed reduced levels of viral DNA synthesis throughout the first two weeks of postnatal development and the appearance of viral replication intermediates was delayed by at least a day compared to the Cre(&#x02212;) mice (<xref ref-type="fig" rid="pone-0005489-g003">Figure 3</xref>). Likewise, the sCre(&#x0002b;) mice displayed a drastic reduction in viral replication consistent with their much lower level of HBV transcripts (<xref ref-type="fig" rid="pone-0005489-g002">Figures 2</xref> and <xref ref-type="fig" rid="pone-0005489-g003">3</xref>) and considerably lower levels of HNF4&#x003b1; expression (<xref ref-type="fig" rid="pone-0005489-g001">Figure 1D</xref>). Therefore it appears that under normal physiological conditions a single transcription factor, HNF4&#x003b1;, controls the early developmental expression of HBV transcripts and consequently viral replication <italic>in vivo</italic>.</p></sec></sec><sec id="s3"><title>Discussion</title><p>HNF4&#x003b1; binds the proximal regulatory element of the nucleocapsid promoter and activates the expression of the HBV 3.5kb pregenomic RNA in cell culture <xref ref-type="bibr" rid="pone.0005489-Tang2">&#x0005b;9&#x0005d;</xref>. Likewise, the analysis of HBV transcription and replication throughout early postnatal development in wild-type HBV transgenic mice and mice conditionally deleted for HNF4&#x003b1; suggest that it serves the same function <italic>in vivo</italic>. HNF4&#x003b1; levels increase in the liver throughout the first two weeks of postnatal development and is associated with a concomitant increase in both HBV RNA transcripts and DNA replication intermediates. The liver-specific conditional disruption of HNF4&#x003b1; during this period of development was associated with two distinct phenotypes. Mice with a severe HNF4&#x003b1; deficiency in the liver displayed reduced growth, altered glucose homeostasis and a postnatal lethal phenotype. These mice synthesized limited amounts of HBV transcripts and replication intermediates. Mice that were close to displaying a normal phenotype with respect to growth and glucose homeostasis exhibited a modest decrease in liver HNF4&#x003b1; levels that was associated with a similar decrease in both viral RNA and DNA synthesis. These observations indicate that HBV transcription and hence viral replication is dependent on HNF4&#x003b1;. Although it is likely that HNF4&#x003b1; directly activates HBV transcription <xref ref-type="bibr" rid="pone.0005489-Tang2">&#x0005b;9&#x0005d;</xref>, it is also possible that HNF4&#x003b1; might control the expression of additional factors necessary for efficient viral transcription and replication <italic>in vivo</italic>. Additionally, the hepatotoxicity resulting from extensive HNF4&#x003b1; loss may contribute to the observed reduction in HBV transcription and replication by unknown mechanisms.</p><p>These studies highlight an interesting relationship between HBV biosynthesis and liver-specific gene expression. We show HNF4&#x003b1; is essential <italic>in vivo</italic> to sustain active viral transcription and subsequent replication. Similarly, HNF4&#x003b1; is required for HBV host viability. The absence of HNF4&#x003b1; or its conditional loss from the liver is fatal in the mouse <xref ref-type="bibr" rid="pone.0005489-Hayhurst1">&#x0005b;10&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005489-Chen1">&#x0005b;12&#x0005d;</xref>. Haploinsufficiency of HNF4&#x003b1; in man is responsible for maturity onset diabetes of the young type 1 (MODY1) <xref ref-type="bibr" rid="pone.0005489-Yamagata1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005489-Shih1">&#x0005b;19&#x0005d;</xref>. Humans with a complete loss of HNF4&#x003b1; have not been reported presumably because, as in mice, it results in early embryonic lethality. Curiously, the adaptation of HBV to utilize HNF4&#x003b1;, an essential host gene product, guarantees constitutive replication of its genome as long as the host is viable. This adaptation may contribute to HBV persistence and offer the virus a significant selective advantage over other pathogens that utilize cellular components that are less important to host survival.</p><p>The vast majority of HBV infections acquired in adolescence and early adulthood are successfully cleared by the host. In contrast, most HBV infections that occur at birth result in chronic infection <xref ref-type="bibr" rid="pone.0005489-Dienstag1">&#x0005b;20&#x0005d;</xref> despite the ability of neonates to mount an antiviral immune response if vaccinated <xref ref-type="bibr" rid="pone.0005489-DelCanho1">&#x0005b;21&#x0005d;</xref>. The parallel increase in HNF4&#x003b1; expression and HBV biosynthesis levels observed during postnatal development in our study suggest that neonatal HBV infection is associated with a slow developmentally regulated increase in viral transcription, replication and antigen expression which may contribute to life long chronic infection <xref ref-type="bibr" rid="pone.0005489-Dienstag1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005489-Milich1">&#x0005b;22&#x0005d;</xref>. Therapeutic interventions that alter the expression levels of viral gene products at this stage of development, such as the fibrate class of hyperlipidemic drugs <xref ref-type="bibr" rid="pone.0005489-Guidotti2">&#x0005b;14&#x0005d;</xref>, might modulate the immune response of the host to viral antigens and help immunological resolution of these neonatal infections.</p><p>The observation that HBV is critically dependent on at least one cellular factor offers a unique target for antiviral therapy. However this opportunity comes with the difficult challenge of inhibiting HNF4&#x003b1; without completely eliminating its essential cellular functions. Nevertheless, mice exhibiting only a modest decrease in HNF4&#x003b1; levels displayed a detectable reduction in HBV RNA and DNA levels while maintaining virtually normal growth and glucose homeostasis (<xref ref-type="fig" rid="pone-0005489-g001">Figure 1</xref>). Furthermore, newborn pups express enough HNF4&#x003b1; for viability but not enough to support HBV replication. If HNF4&#x003b1; activity levels can be attenuated clinically to limit HBV biosynthesis while minimally affecting liver physiology, this might offer a novel therapeutic strategy to complement currently available antiviral drugs targeting the HBV reverse transcriptase <xref ref-type="bibr" rid="pone.0005489-Dienstag1">&#x0005b;20&#x0005d;</xref>. Metformin, a drug widely used to treat type 2 diabetes, reduces peroxisome proliferator-activated receptor &#x003b3; coactivator 1&#x003b1; expression and gluconeogenesis in the liver suggesting pharmacological intervention may be successful in decreasing HNF4&#x003b1;-dependent HBV transcription and replication <xref ref-type="bibr" rid="pone.0005489-Shaw1">&#x0005b;23&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005489-Shlomai1">&#x0005b;24&#x0005d;</xref>.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Ethics statement</title><p>All animal experiments were performed according to institutional guidelines with Institutional Biosafety and Animal Care Committee approval.</p></sec><sec id="s4b"><title>Transgenic mice</title><p>We bred HBV transgenic mice (lineage 1.3.32) <xref ref-type="bibr" rid="pone.0005489-Guidotti1">&#x0005b;13&#x0005d;</xref> with mice carrying a floxed HNF4&#x003b1; (<italic>HNF4&#x003b1;</italic><sup>fl/fl</sup>) allele <xref ref-type="bibr" rid="pone.0005489-Hayhurst1">&#x0005b;10&#x0005d;</xref> and albumin Cre (lineage B6.Cg-Tg(Alb-cre)21Mgn/J, Jackson Laboratory) transgene (AlbCre) <xref ref-type="bibr" rid="pone.0005489-Postic1">&#x0005b;15&#x0005d;</xref> to generate HBVAlbCreHNF4&#x003b1;<sup>fl/fl</sup> transgenic mice. All the mouse strains had been crossed for twelve generations onto the SV129 genetic background <xref ref-type="bibr" rid="pone.0005489-Lee1">&#x0005b;25&#x0005d;</xref> prior to generating the HBVAlbCreHNF4&#x003b1;<sup>fl/fl</sup> transgenic mice. Mice were screened for the HBV transgene, the AlbCre transgene and the floxed HNF4&#x003b1; allele by polymerase chain reaction (PCR) analysis of tail DNA <xref ref-type="bibr" rid="pone.0005489-Anderson1">&#x0005b;26&#x0005d;</xref>. The HBV transgene was identified by PCR analysis using the oligonucleotides, <named-content content-type="gene">5&#x02032;-TCGATACCTGAACCTTTACCCCGTTGCCCG-3&#x02032;</named-content> (oligo XpHNF4-1, HBV coordinates 1133 to 1159) and <named-content content-type="gene">5&#x02032;-TCGAATTGCTGAGAGTCCAAGAGTCCTCTT-3&#x02032;</named-content> (oligo CpHNF4-2, HBV coordinates 1683 to 1658), and 1 &#x000b5;l of tail DNA. A PCR product of 551 base pairs indicated the presence of the HBV transgene. The AlbCre transgene was identified by PCR analysis using the oligonucleotides, <named-content content-type="gene">5&#x02032;-CCAGCTAAACATGCTTCATCGTCG-3&#x02032;</named-content> (oligo CRE-1) and <named-content content-type="gene">5&#x02032;-ATTCTCCCACCGTCAGTACGTGAG-3&#x02032;</named-content> (oligo CRE-2), and 1 &#x000b5;l of tail DNA. A PCR product of 300 base pairs indicated the presence of the Cre transgene. The HNF4&#x003b1; wild-type and floxed alleles were identified by PCR analysis using the oligonucleotides, <named-content content-type="gene">5&#x02032;-AGAATGACCCTGAAGCACCAGG-3&#x02032;</named-content> (oligo prH4GTLP1-F1) and <named-content content-type="gene">5&#x02032;-GCCAGAGGTCTGTGAAACAAGG-3&#x02032;</named-content> (oligo prH4GT-LP1-R1), and 1 &#x000b5;l of tail DNA. PCR products of 180 and 241 base pairs indicated the presence of the wild-type and floxed HNF4&#x003b1; alleles, respectively <xref ref-type="bibr" rid="pone.0005489-Hayhurst1">&#x0005b;10&#x0005d;</xref>. Serum glucose levels were measured using a SureStep blood glucose meter (Lifescan).</p></sec><sec id="s4c"><title>HBV DNA and RNA analysis</title><p>Total DNA and RNA were isolated from liver of HBV transgenic mice as described <xref ref-type="bibr" rid="pone.0005489-Sambrook1">&#x0005b;27&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005489-Chomczynski1">&#x0005b;28&#x0005d;</xref>. DNA (Southern) filter hybridization analyses were performed using 20 &#x000b5;g of <italic>Hin</italic>dIII digested DNA <xref ref-type="bibr" rid="pone.0005489-Sambrook1">&#x0005b;27&#x0005d;</xref>. Filters were probed with <sup>32</sup>P-labeled HBV<italic>ayw</italic> genomic DNA <xref ref-type="bibr" rid="pone.0005489-Galibert1">&#x0005b;29&#x0005d;</xref> to detect HBV sequences. RNA (Northern) filter hybridization analyses were performed using 10 &#x000b5;g of total cellular RNA as described <xref ref-type="bibr" rid="pone.0005489-Sambrook1">&#x0005b;27&#x0005d;</xref>. Filters were probed with <sup>32</sup>P-labeled HBV<italic>ayw</italic> genomic DNA to detect HBV sequences and mouse glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA to detect the GAPDH transcript used as an internal control <xref ref-type="bibr" rid="pone.0005489-Sabath1">&#x0005b;30&#x0005d;</xref>. Filter hybridization analyses were quantitated by phosphorimaging using a Packard Cyclone Storage Phosphor System.</p><p>Reverse transcription-quantitative polymerase chain reaction was used to measure the level of HNF4&#x003b1; transcripts in mouse liver RNA. After DNase I treatment, 1 &#x000b5;g of RNA was used for cDNA synthesis using the TaqMan reverse transcription reagents (Applied Biosystems, Foster City, CA), followed by real-time PCR quantification using SYBR Green and an Applied Biosystems 7300 real-time thermocycler (Applied Biosystems). Thermal cycling consisted of an initial denaturation step for 10 min at 95&#x000b0;C followed by 40 cycles of denaturation (15 sec at 95&#x000b0;C) and annealing/extension (1 min at 60&#x000b0;C). The relative HNF4&#x003b1; RNA expression levels were estimated using the &#x00394;&#x00394;Ct method with normalization to mouse GAPDH RNA. The PCR primers used were <named-content content-type="gene">5&#x02032;-TCAACGCGCTCCTGC-3&#x02032;</named-content> (HNF4&#x003b1; exon 4 sense primer), <named-content content-type="gene">5&#x02032;-AATCTTCTTTGCCCGAATGT-3&#x02032;</named-content> (HNF4&#x003b1; exon 5 antisense primer), <named-content content-type="gene">5&#x02032;-TCTGGAAAGCTGTGGCGTG-3&#x02032;</named-content> (mouse GAPDH sense primer) and <named-content content-type="gene">5&#x02032;-CCAGTGAGCTTCCCGTTCAG-3&#x02032;</named-content> (mouse GAPDH antisense primer).</p></sec></sec></body><back><ack><p>We thank Luca G. Guidotti and Francis V. Chisari (The Scripps Research Institute, La Jolla, CA) for providing the HBV transgenic mice. We thank Linda Kenney, Bellur Prabhakar, David Ucker and William Walden for many helpful discussions and critical reading of the manuscript. We are grateful to Iain McLachlan for the photographic imaging of the HBV transgenic mice.</p></ack><ref-list><title>References</title><ref id="pone.0005489-Geeraert1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geeraert</surname><given-names>L</given-names></name><name><surname>Kraus</surname><given-names>G</given-names></name><name><surname>Pomerantz</surname><given-names>RJ</given-names></name></person-group><year>2008</year><article-title>Hide-and-seek: the challenge of viral persistence in HIV-1 Infection.</article-title><source>Annu Rev Med</source><volume>59</volume><fpage>487</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">17845138</pub-id></citation></ref><ref id="pone.0005489-Knipe1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knipe</surname><given-names>DM</given-names></name><name><surname>Cliffe</surname><given-names>A</given-names></name></person-group><year>2008</year><article-title>Chromatin control of herpes simplex virus lytic and latent infection.</article-title><source>Nat Rev Micro</source><volume>6</volume><fpage>211</fpage><lpage>221</lpage></citation></ref><ref id="pone.0005489-Stanley1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>M</given-names></name></person-group><year>2008</year><article-title>Immunobiology of HPV and HPV vaccines.</article-title><source>Gynecol Oncol</source><volume>109</volume><fpage>S15</fpage><lpage>S21</lpage><pub-id pub-id-type="pmid">18474288</pub-id></citation></ref><ref id="pone.0005489-Gale1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gale</surname><given-names>M</given-names></name><name><surname>Foy</surname><given-names>EM</given-names></name></person-group><year>2005</year><article-title>Evasion of intracellular host defence by hepatitis C virus.</article-title><source>Nature</source><volume>436</volume><fpage>939</fpage><lpage>945</lpage><pub-id pub-id-type="pmid">16107833</pub-id></citation></ref><ref id="pone.0005489-Lok1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lok</surname><given-names>AS</given-names></name><name><surname>Heathcote</surname><given-names>EJ</given-names></name><name><surname>Hoofnagle</surname><given-names>JH</given-names></name></person-group><year>2001</year><article-title>Management of hepatitis B: 2000 - Summary of a workshop.</article-title><source>Gastroenterology</source><volume>120</volume><fpage>1828</fpage><lpage>1853</lpage><pub-id pub-id-type="pmid">11375963</pub-id></citation></ref><ref id="pone.0005489-Lavanchy1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lavanchy</surname><given-names>D</given-names></name></person-group><year>2004</year><article-title>Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.</article-title><source>J Viral Hepat</source><volume>11</volume><fpage>97</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">14996343</pub-id></citation></ref><ref id="pone.0005489-Will1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Will</surname><given-names>H</given-names></name><name><surname>Reiser</surname><given-names>W</given-names></name><name><surname>Weimer</surname><given-names>T</given-names></name><name><surname>Pfaff</surname><given-names>E</given-names></name><name><surname>Buscher</surname><given-names>M</given-names></name><etal/></person-group><year>1987</year><article-title>Replication strategy of human hepatitis B virus.</article-title><source>J Virol</source><volume>61</volume><fpage>904</fpage><lpage>911</lpage><pub-id pub-id-type="pmid">3806799</pub-id></citation></ref><ref id="pone.0005489-Tang1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Banks</surname><given-names>KE</given-names></name><name><surname>Anderson</surname><given-names>AL</given-names></name><name><surname>McLachlan</surname><given-names>A</given-names></name></person-group><year>2001</year><article-title>Hepatitis B virus transcription and replication.</article-title><source>Drug News Perspect</source><volume>14</volume><fpage>325</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">12813595</pub-id></citation></ref><ref id="pone.0005489-Tang2"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>McLachlan</surname><given-names>A</given-names></name></person-group><year>2001</year><article-title>Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism.</article-title><source>Proc Natl Acad Sci USA</source><volume>98</volume><fpage>1841</fpage><lpage>1846</lpage><pub-id pub-id-type="pmid">11172038</pub-id></citation></ref><ref id="pone.0005489-Hayhurst1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayhurst</surname><given-names>GP</given-names></name><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Lambert</surname><given-names>G</given-names></name><name><surname>Ward</surname><given-names>JM</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group><year>2001</year><article-title>Hepatocyte nuclear factor 4&#x003b1; (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis.</article-title><source>Mol Cell Biol</source><volume>21</volume><fpage>1393</fpage><lpage>1403</lpage><pub-id pub-id-type="pmid">11158324</pub-id></citation></ref><ref id="pone.0005489-Parviz1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parviz</surname><given-names>F</given-names></name><name><surname>Matullo</surname><given-names>C</given-names></name><name><surname>Garrison</surname><given-names>WD</given-names></name><name><surname>Savatski</surname><given-names>L</given-names></name><name><surname>Adamson</surname><given-names>JW</given-names></name><etal/></person-group><year>2003</year><article-title>Hepatocyte nuclear factor 4&#x003b1; controls the development of a hepatic epithelium and liver morphogenesis.</article-title><source>Nature Genet</source><volume>34</volume><fpage>292</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">12808453</pub-id></citation></ref><ref id="pone.0005489-Chen1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WS</given-names></name><name><surname>Manova</surname><given-names>K</given-names></name><name><surname>Weinstein</surname><given-names>DC</given-names></name><name><surname>Duncan</surname><given-names>SA</given-names></name><name><surname>Plump</surname><given-names>AS</given-names></name><etal/></person-group><year>1994</year><article-title>Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos.</article-title><source>Genes Dev</source><volume>8</volume><fpage>2466</fpage><lpage>2477</lpage><pub-id pub-id-type="pmid">7958910</pub-id></citation></ref><ref id="pone.0005489-Guidotti1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guidotti</surname><given-names>LG</given-names></name><name><surname>Matzke</surname><given-names>B</given-names></name><name><surname>Schaller</surname><given-names>H</given-names></name><name><surname>Chisari</surname><given-names>FV</given-names></name></person-group><year>1995</year><article-title>High-level hepatitis B virus replication in transgenic mice.</article-title><source>J Virol</source><volume>69</volume><fpage>6158</fpage><lpage>6169</lpage><pub-id pub-id-type="pmid">7666518</pub-id></citation></ref><ref id="pone.0005489-Guidotti2"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guidotti</surname><given-names>LG</given-names></name><name><surname>Eggers</surname><given-names>CM</given-names></name><name><surname>Raney</surname><given-names>AK</given-names></name><name><surname>Chi</surname><given-names>SY</given-names></name><name><surname>Peters</surname><given-names>JM</given-names></name><etal/></person-group><year>1999</year><article-title><italic>In vivo</italic> regulation of hepatitis B virus replication by peroxisome proliferators.</article-title><source>J Virol</source><volume>73</volume><fpage>10377</fpage><lpage>10386</lpage><pub-id pub-id-type="pmid">10559356</pub-id></citation></ref><ref id="pone.0005489-Postic1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Postic</surname><given-names>C</given-names></name><name><surname>Shiota</surname><given-names>M</given-names></name><name><surname>Niswender</surname><given-names>KD</given-names></name><name><surname>Jetton</surname><given-names>TL</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><year>1999</year><article-title>Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase.</article-title><source>J Biol Chem</source><volume>274</volume><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">9867845</pub-id></citation></ref><ref id="pone.0005489-Fenech1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fenech</surname><given-names>FF</given-names></name><name><surname>Bannister</surname><given-names>WH</given-names></name><name><surname>Grech</surname><given-names>JL</given-names></name></person-group><year>1967</year><article-title>Hepatitis with biliverdinaemia in association with indomethacin therapy.</article-title><source>Br Med J</source><volume>3</volume><fpage>155</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">6028104</pub-id></citation></ref><ref id="pone.0005489-Rhee1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>J</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Yoon</surname><given-names>JC</given-names></name><name><surname>Puigserver</surname><given-names>P</given-names></name><name><surname>Fan</surname><given-names>ML</given-names></name><etal/></person-group><year>2003</year><article-title>Regulation of hepatic fasting response by PPAR&#x003b3; coactivator-1&#x003b1; (PGC-1): Requirement for hepatocyte nuclear factor 4&#x003b1; in gluconeogenesis.</article-title><source>Proc Natl Acad Sci USA</source><volume>100</volume><fpage>4012</fpage><lpage>4017</lpage><pub-id pub-id-type="pmid">12651943</pub-id></citation></ref><ref id="pone.0005489-Yamagata1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamagata</surname><given-names>K</given-names></name><name><surname>Furuta</surname><given-names>H</given-names></name><name><surname>Oda</surname><given-names>N</given-names></name><name><surname>Kaisaki</surname><given-names>PJ</given-names></name><name><surname>Menzel</surname><given-names>S</given-names></name><etal/></person-group><year>1996</year><article-title>Mutations in the hepatocyte nuclear factor-4&#x003b1; gene in maturity- onset diabetes of the young (MODY1).</article-title><source>Nature</source><volume>384</volume><fpage>458</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">8945471</pub-id></citation></ref><ref id="pone.0005489-Shih1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>DQ</given-names></name><name><surname>Dansky</surname><given-names>HM</given-names></name><name><surname>Fleisher</surname><given-names>M</given-names></name><name><surname>Assmann</surname><given-names>G</given-names></name><name><surname>Fajans</surname><given-names>SS</given-names></name><etal/></person-group><year>2000</year><article-title>Genotype/phenotype relationships in HNF-4&#x003b1;/MODY1 - Haploinsufficiency is associated with reduced apolipoprotein(AII), apolipoprotein(CIII), lipoprotein(a), and triglyceride levels.</article-title><source>Diabetes</source><volume>49</volume><fpage>832</fpage><lpage>837</lpage><pub-id pub-id-type="pmid">10905494</pub-id></citation></ref><ref id="pone.0005489-Dienstag1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dienstag</surname><given-names>JL</given-names></name></person-group><year>2008</year><article-title>Hepatitis B virus infection.</article-title><source>N Engl J Med</source><volume>359</volume><fpage>1486</fpage><lpage>1500</lpage><pub-id pub-id-type="pmid">18832247</pub-id></citation></ref><ref id="pone.0005489-DelCanho1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Del Canho</surname><given-names>R</given-names></name><name><surname>Grosheide</surname><given-names>PM</given-names></name><name><surname>Voogd-Schotanus</surname><given-names>M</given-names></name><name><surname>Huisman</surname><given-names>WM</given-names></name><name><surname>Heijtink</surname><given-names>RA</given-names></name><etal/></person-group><year>1994</year><article-title>Immunogenicity of two different dosages (10 and 5 &#x000b5;g) of recombinant DNA hepatitis B vaccine in healthy neonates.</article-title><source>Vaccine</source><volume>12</volume><fpage>1323</fpage><lpage>1326</lpage><pub-id pub-id-type="pmid">7856298</pub-id></citation></ref><ref id="pone.0005489-Milich1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milich</surname><given-names>DR</given-names></name><name><surname>Jones</surname><given-names>JE</given-names></name><name><surname>Hughes</surname><given-names>JL</given-names></name><name><surname>Price</surname><given-names>J</given-names></name><name><surname>Raney</surname><given-names>AK</given-names></name><etal/></person-group><year>1990</year><article-title>Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance <italic>in utero</italic>?</article-title><source>Proc Natl Acad Sci USA</source><volume>87</volume><fpage>6599</fpage><lpage>6603</lpage><pub-id pub-id-type="pmid">2395863</pub-id></citation></ref><ref id="pone.0005489-Shaw1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>RJ</given-names></name><name><surname>Lamia</surname><given-names>KA</given-names></name><name><surname>Vasquez</surname><given-names>D</given-names></name><name><surname>Koo</surname><given-names>SH</given-names></name><name><surname>Bardeesy</surname><given-names>N</given-names></name><etal/></person-group><year>2005</year><article-title>The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin.</article-title><source>Science (New York), N Y</source><volume>310</volume><fpage>1642</fpage><lpage>1646</lpage></citation></ref><ref id="pone.0005489-Shlomai1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shlomai</surname><given-names>A</given-names></name><name><surname>Paran</surname><given-names>N</given-names></name><name><surname>Shaul</surname><given-names>Y</given-names></name></person-group><year>2006</year><article-title>PGC-1&#x003b1; controls hepatitis B virus through nutritional signals.</article-title><source>Proc Natl Acad Sci USA</source><volume>103</volume><fpage>16003</fpage><lpage>16008</lpage><pub-id pub-id-type="pmid">17043229</pub-id></citation></ref><ref id="pone.0005489-Lee1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SST</given-names></name><name><surname>Pineau</surname><given-names>T</given-names></name><name><surname>Drago</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Owens</surname><given-names>JW</given-names></name><etal/></person-group><year>1995</year><article-title>Targeted disruption of the &#x003b1; isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators.</article-title><source>Mol Cell Biol</source><volume>15</volume><fpage>3012</fpage><lpage>3022</lpage><pub-id pub-id-type="pmid">7539101</pub-id></citation></ref><ref id="pone.0005489-Anderson1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>AL</given-names></name><name><surname>Banks</surname><given-names>KE</given-names></name><name><surname>Pontoglio</surname><given-names>M</given-names></name><name><surname>Yaniv</surname><given-names>M</given-names></name><name><surname>McLachlan</surname><given-names>A</given-names></name></person-group><year>2005</year><article-title>Alpha/beta interferon differentially modulates the clearance of cytoplasmic encapsidated replication intermediates and nuclear covalently closed circular hepatitis B virus (HBV) DNA from the livers of hepatocyte nuclear factor 1&#x003b1;-null HBV transgenic mice.</article-title><source>J Virol</source><volume>79</volume><fpage>11045</fpage><lpage>11052</lpage><pub-id pub-id-type="pmid">16103155</pub-id></citation></ref><ref id="pone.0005489-Sambrook1"><label>27</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Sambrook</surname><given-names>J</given-names></name><name><surname>Fritsch</surname><given-names>EF</given-names></name><name><surname>Maniatis</surname><given-names>T</given-names></name></person-group><year>1989</year><article-title>Molecular cloning: a laboratory manual.</article-title><publisher-loc>New York</publisher-loc><publisher-name>Cold Spring Harbor Laboratory Press</publisher-name></citation></ref><ref id="pone.0005489-Chomczynski1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chomczynski</surname><given-names>P</given-names></name><name><surname>Sacchi</surname><given-names>N</given-names></name></person-group><year>1987</year><article-title>Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.</article-title><source>Anal Biochem</source><volume>162</volume><fpage>156</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">2440339</pub-id></citation></ref><ref id="pone.0005489-Galibert1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galibert</surname><given-names>F</given-names></name><name><surname>Mandart</surname><given-names>E</given-names></name><name><surname>Fitoussi</surname><given-names>F</given-names></name><name><surname>Tiollais</surname><given-names>P</given-names></name><name><surname>Charnay</surname><given-names>P</given-names></name></person-group><year>1979</year><article-title>Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in <italic>E. coli</italic>.</article-title><source>Nature</source><volume>281</volume><fpage>646</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">399327</pub-id></citation></ref><ref id="pone.0005489-Sabath1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabath</surname><given-names>DE</given-names></name><name><surname>Broome</surname><given-names>HE</given-names></name><name><surname>Prystowsky</surname><given-names>MB</given-names></name></person-group><year>1990</year><article-title>Glyceraldehyde-3-phosphate dehydrogenase mRNA is a major interleukin 2- induced transcript in a cloned T-helper lymphocyte.</article-title><source>Gene</source><volume>91</volume><fpage>185</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">2145197</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by Public Health Service grants AI30070 from the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 